SANUWAVE Health, Inc.

April 04, 2017 08:30 ET

Sanuwave Health Reports Record Revenue in 2016 and Provides a Business Update

SUWANEE, GA--(Marketwired - Apr 4, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) reported financial results for the year ended December 31, 2016 with the SEC on Friday, March 31, 2017 and today provided a business update. The Company will host a conference call today, April 4, 2017, at 10:00 a.m. Eastern Time.

Highlights of 2016 and recent weeks:

  • Recorded record revenue of $1.4 million for the year that included record sales of 45 devices. This is our highest revenue since becoming public in 2009.

  • Released the 24 week data from the pivotal trials investigating the use of dermaPACE for the treatment of diabetic foot ulcers on March 24, 2016. In July 2016, the Company submitted to the FDA a de novo petition requesting the Agency review the classification of the dermaPACE as a Class II device. The Company presented a summary of data analyses of the supplemental trial and of combined data from both Phase III DFU trials. 

  • Focusing on international market and investigating opportunities to address the needs of each country. We are concentrating on three types of relationships: distributors, joint ventures, and exclusivity agreements.

    -- Currently in discussions with companies in North America, South America, United Kingdom, Eastern Europe, Scandinavia, Asia, and the Middle East.
    -- We have signed non-disclosure agreements with various companies in Taiwan, Indonesia, Vietnam, and South Africa.

  • Completed a public equity offering for $1.8 million in gross proceeds from the sale of the Company's stock and warrants which closed on April 15, 2016.

  • Completed a private equity offering for $1.7 million in gross proceeds from the sale of the Company's stock and warrants which closed on September 23, 2016.

  • Received three patents as follows:

    -- Canadian Pat. No. 2,909,661 from the Canadian Intellectual Property Office entitled "Apparatuses and Methods for Generating Shock Waves for Use in the Energy Industry" that has a patent life to April 2034. The patent includes twenty claims relating to the use of shock waves, generated with laser systems, for hydraulic fracturing of rock formations, which can be employed in both secondary and tertiary oil recovery.
    -- U.S. patent number 9,522,011, titled "Shock Wave Applicator with Movable Electrode" that has an expiration date of July 8, 2030. This patent relates to a new electrohydraulic applicator that has either ellipsoidal, parabolic, or spherical reflectors with their aperture intersecting reflector's long axis at a non-perpendicular angle and which allows the shock wave-generating electrodes to be adjusted up and down relatively to the focal point.
    -- U.S. patent number 9,566,209 titled "Shock Wave Electrodes with Fluid Holes" that has an expiration date on June 21, 2033. This patent relates to a new construction of the spark gap electrodes used to generate acoustic pressure shock waves in SANUWAVE's devices, which allows a longer useful life for the applicators.

"We had the most eventful year in SANUWAVE's history in 2016. We grew international revenue by 40%, successfully submitted a de novo petition for the dermaPACE device to the FDA and increased our number of patents received and/or applied for from fifty-three to sixty-six" stated Kevin A. Richardson II, CEO and Chairman of the board of SANUWAVE. "In 2017, we expect to add seven to ten new regions or countries to our international portfolio, launch clinical work domestically in the tangential areas for growth and expand our board of directors and scientific advisory board. We also look forward working with the FDA to get our dermaPACE device approved for use in the United States."

2016 Financial Results

Year Ended December 31, 201 Financial Results

Revenues for the year ended December 31, 2016 were $1,376,063, compared to $965,501 for the same period in 2015, an increase of $410,562, or 43%. Revenue resulted primarily from sales in Europe, Asia and Asia/Pacific of our orthoPACE devices and related applicators. The increase in revenue for 2016 is primarily due to an increase in sales of 17 orthoPACE devices in Asia/Pacific and the European Community, as compared to the prior year, as well as higher sales of new and refurbished applicators due to increased devices in use.

Operating expenses for the year ended December 31, 2016 were $4,127,433, compared to $5,118,317 for the prior year, a decrease of $990,884. Research and development expenses decreased by $1,044,179, primarily as a result of lower consultant expenses related to the calculation and analysis of the data that was performed in late 2015 and early 2016. In addition, there were no expenses in 2016 related to the clinical trial as that was completed in 2015. General and administrative expenses decreased by $61,356, primarily due to reduced salary, benefits and travel expenses. This decrease was partially offset by increased consulting expenses related to the potential commercialization of dermaPACE and increased accounting fees in 2016 related to consulting on complex financial transactions and SEC registration filings.

Net loss for 2016 was $6,439,040, or ($0.08) per share, compared with a net loss of $4,810,285, or ($0.08) per share in 2015, which is an increase in the net loss of $1,628,755, or 34%. The increase in the net loss for 2016 was a result of increased non-cash expense for the valuation of outstanding warrants and was partially offset by the reduced operating expenses in 2016 noted above.

On December 31, 2016, the Company has cash and cash equivalents of $133,571 compared to $152,930 as of December 31, 2015, a decrease of $19,359. For the years ended December 31, 2016 and 2015, net cash used by operating activities was $3,199,453 and $3,473,456, respectively, a decrease of $274,003, or 8%. The decrease was primarily due to the decreased total operating expenses in 2016, as compared to 2015, of $1,105,535, which was partially offset by increase in accounts receivable of $430,583 and a decrease in accrued employee compensation of $415,998. Net cash used by investing activities in 2016 was $8,770 as compared to net cash provided by investing activities in 2015 of $100,000 from the sale of assets held for sale. Net cash provided by financing activities for the year ended December 31, 2016 was $3,207,771, which primarily consisted of the net proceeds from 2016 Public Offering of $1,596,855, 2016 Private Placement of $1,528,200, and proceeds from warrant exercises of $67,466. There was no net cash provided by financing activities in 2015. Cash and cash equivalents decreased by $19,359 for the year ended December 31, 2016 and cash and cash equivalents decreased by $3,394,141 for the year ended December 31, 2015.

Conference Call
The Company will also host a conference call on Tuesday, April 4, 2017, beginning at 10AM Eastern Time to discuss the 2016 financial results, provide a business update and answer questions. Shareholders and other interested parties can participate in the conference call by dialing 866-682-6100 (U.S.) or 862-255-5401 (international) or via webcast at

A replay of the conference call will be available beginning two hours after its completion through April 18, 2017, by dialing 877-481-4010 (U.S.) or 919-882-2331 (international) and entering Conference ID 10303.

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. ( is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's de novo petition review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit


December 31, 2016 and 2015  
    2016     2015  
CURRENT ASSETS                
  Cash and cash equivalents   $ 133,571     $ 152,930  
  Accounts receivable, net of allowance for doubtful accounts     460,799       74,454  
  Inventory     231,953       284,908  
  Prepaid expenses     87,823       123,988  
  TOTAL CURRENT ASSETS     914,146       636,280  
PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation     76,938       4,228  
OTHER ASSETS     13,786       11,097  
INTANGIBLE ASSETS, at cost, less accumulated amortization     -       306,756  
  TOTAL ASSETS   $ 1,004,870     $ 958,361  
  Accounts payable   $ 712,964     $ 509,266  
  Accrued expenses     375,088       359,374  
  Accrued employee compensation     64,860       241,542  
  Interest payable, related parties     109,426       239,803  
  Short term loan, net     47,440       -  
  Warrant liability     1,242,120       138,100  
  Notes payable, related parties, net     5,364,572       -  
  TOTAL CURRENT LIABILITIES     7,916,470       1,488,085  
  Notes payable, related parties, net     -       5,348,112  
  TOTAL LIABILITIES     7,916,470       6,836,197  
PREFERRED STOCK, SERIES A CONVERTIBLE, par value $0.001, 6,175 authorized; 6,175 shares issued and 0 shares outstanding in 2016 and 2015     -       -  
PREFERRED STOCK, SERIES B CONVERTIBLE, par value $0.001, 293 authorized; 293 shares issued and 0 shares outstandingin 2016 and 2015, respectively     -       -  
PREFERRED STOCK - UNDESIGNATED, par value $0.001, 4,993,532 shares authorized; no shares issued and outstanding     -       -  
COMMON STOCK, par value $0.001, 350,000,000 shares authorized; 137,219,968 and 63,056,519 issued and outstanding in 2016 and 2015, respectively     137,220       63,057  
ADDITIONAL PAID-IN CAPITAL     92,436,697       87,086,677  
ACCUMULATED DEFICIT     (99,433,448 )     (92,994,408 )
  TOTAL STOCKHOLDERS' DEFICIT     (6,911,600 )     (5,877,836 )
Years Ended December 31, 2016 and 2015  
    2016     2015  
REVENUES   $ 1,376,063     $ 965,501  
COST OF REVENUES (exclusive of depreciation and amortization shown below)     565,129       284,962  
OPERATING EXPENSES                
  Research and development     1,128,640       2,172,819  
  General and administrative     2,673,773       2,735,129  
  Depreciation     19,858       3,612  
  Amortization     306,756       306,757  
  Gain of sale of assets, property and equipment     (1,594 )     (100,000 )
    TOTAL OPERATING EXPENSES     4,127,433       5,118,317  
    OPERATING LOSS     (3,316,499 )     (4,437,778 )
OTHER INCOME (EXPENSE)                
  Gain (loss) on warrant valuation adjustment and conversion     (2,223,718 )     58,515  
  Interest expense, net     (854,980 )     (399,832 )
  Amortization of debt discount     (31,514 )     (12,358 )
  Loss on foreign currency exchange     (12,329 )     (18,832 )
    TOTAL OTHER INCOME (EXPENSE), NET     (3,122,541 )     (372,507 )
    NET LOSS     (6,439,040 )     (4,810,285 )
  Foreign currency translation adjustments     (18,907 )     (20,685 )
    TOTAL COMPREHENSIVE LOSS   $ (6,457,947 )   $ (4,830,970 )
LOSS PER SHARE:                
  Net loss - basic and diluted   $ (0.06 )   $ (0.08 )
  Weighted average shares outstanding - basic and diluted     107,619,869       63,025,202  
Years Ended December 31, 2016 and 2015  
    2016     2015  
Net loss   $ (6,439,040 )   $ (4,810,285 )
  Adjustments to reconcile loss from continuing operations to net cash used by operating activities                
    Amortization     306,756       306,757  
    Depreciation     19,858       3,612  
    Change in allowance for doubtful accounts     26,233       (6,055 )
    Stock-based compensation - employees, directors and advisors     547,842       504,534  
    Warrants issued for services     186,410       -  
    (Gain) loss on warrant valuation adjustment     2,223,718       (58,515 )
    Amortization of debt issuance costs     225,786       -  
    Loss on conversion option of promissory notes payable     75,422       -  
    Stock issued with convertible debenture     50,100       -  
    Stock issued for consulting services     43,540       -  
    Amortization of debt discount     31,514       12,358  
    Gain on sale of asset, property and equipment     (1,594 )     (100,000 )
    Changes in assets - (increase)/decrease                
      Accounts receivable - trade     (412,578 )     18,005  
      Inventory     (29,249 )     (13,037 )
      Prepaid expenses     36,165       4,562  
      Other     (2,689 )     9  
    Changes in liabilities - increase/(decrease)                
      Accounts payable     203,698       277,426  
      Accrued expenses     15,714       (10,082 )
      Accrued employee compensation     (176,682 )     239,316  
      Interest payable, related parties     (130,377 )     157,939  
    NET CASH USED BY OPERATING ACTIVITIES     (3,199,453 )     (3,473,456 )
    Proceeds from sale of property and equipment     1,594       100,000  
    Purchases of property and equipment     (10,364 )     -  
    Proceeds from 2016 Public Offering, net     1,596,855       -  
    Proceeds from 2016 Private Offering, net     1,528,200       -  
    Proceeds from convertible promissory notes, net     106,000       -  
    Proceeds from convertible debenture, net     175,000       -  
    Proceeds from short term loan     100,000       -  
    Proceeds from warrant exercise     67,466       -  
    Payment of convertible promissory notes     (155,750 )     -  
    Payment of convertible debenture     (210,000 )     -  
EFFECT OF EXCHANGE RATES ON CASH     (18,907 )     (20,685 )
    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS     (19,359 )     (3,394,141 )
    CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 133,571     $ 152,930  
    Cash paid for interest, related parties   $ 630,549     $ 242,904  
    Stock issued with convertible debenture   $ 50,100     $ -  
    Stock issued for services   $ 43,540     $ -  
    Loss on warrant conversion to stock   $ 888,418     $ -  
    Beneficial conversion feature on convertible promissory notes     66,331       -  
    Beneficial conversion feature on convertible debenture     124,900       -  
    Beneficial conversion feature on convertible debt   $ 191,231     $ -  
    Warrants issued for services   $ 186,410     $ -  
    Warrants issued for short tem loan   $ 58,400     $ -  

Contact Information